BCLI News and Press, Brainstorm Cell Therapeutics Inc. From 08/05/21

BrainStorm Cell Therapeutics (NASDAQ:BCLI): Q2 GAAP EPS of -$0.17 beats by $0.05. Cash, cash equivalents, and short-term bank deposits were ~$35M as of June 30, 2021, compared to ~$40.0Mon March 31, 2021. Press Release For further details see: BrainStorm Cell Therapeutics EPS beats by $...

BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update Continuing to assess regulatory strategy for advancing NurOwn® towards potential approval in ALS Conference call and webcast at 8:00 a.m. Eastern Time today PR Newswire ...

BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel GMP certification of three state-of-the-art cleanrooms more than doubles the Company's manufacturing capacity for NurOwn® in Israel PR Newswire ...

BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update PR Newswire NEW YORK , July 26, 2021 /PRNewswire/ --BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets PR Newswire NEW YORK , June 15, 2021 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer o...

Alzheimer’s disease (AD) is the most common cause of dementia, a progressively debilitating neurodegenerative disease that results in declining cognitive functions, inability to form new memories, behavioral disorders, and gradual loss of bodily functions. While older age does not cause...

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...

Recent advances in stem cell technologies, armed with the ability to generate almost any tissue-specific cell types of the body in a dish, human pluripotent stem cells (hPSCs) have drastically moved therapeutic research forward in unprecedented ways. Stem cell-derived cells are increasingly re...

Brainstorm Cell Therapeutics, Inc. is a biotechnology company developing best-in-class autologous cell therapies for treating neurodegenerative diseases including ALS, PMS, Alzheimer's, and others. Brainstorm's modified mesenchymal stem cells are being tested in one ongoing Phase 2 tr...

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting Superior clinical and biomarker outcomes demonstrated with NurOwn exosomes compared to MSC exosomes in Preclinical ARDS Model PR Newswire ...